
Opinion|Videos|January 24, 2024
The Evolving Treatment Landscape in Relapsed/Refractory CLL
Author(s)Mazyar Shadman, MD, MPH
Expert perspective on evolving data and strategies for managing relapsed/refractory CLL.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
Dr Tolaney on SG + Pembrolizumab Biomarker Data in First-Line mTNBC
5

































